Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2019

01-06-2019 | Hepatocellular Carcinoma | Hepatitis C (H Vargas and S Flamm, Section Editors)

Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice

Authors: James C. Connolly, Joseph K. Lim

Published in: Current Hepatology Reports | Issue 2/2019

Login to get access

Abstract

Purpose of Review

Chronic hepatitis C (CHC) infection remains a significant global public health burden and is associated with significant morbidity and mortality due to complications of cirrhosis, liver failure, and hepatocellular carcinoma (HCC). All oral direct-acting antivirals (DAAs) are associated with high rates of sustained virologic response (SVR). Pre-treatment assessment for liver fibrosis remains of high importance as it may impact treatment choice, treatment duration, and signal the presence of cirrhosis for which variceal screening and HCC surveillance are warranted.

Recent Findings

Non-invasive fibrosis assessment tools have largely replaced gold standard liver biopsy in routine clinical practice. Herein, we review key modalities of noninvasive testing with serum and imaging biomarkers, summarize current guideline recommendations, and propose an algorithm for real-world application in clinical practice.

Summary

Careful history and exam, laboratory assessment, liver imaging, and a two-test noninvasive fibrosis strategy can reliably identify cirrhosis in patients with CHC infection.
Literature
1.
2.
Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81.CrossRef
3.
Stanaway JD, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.CrossRefPubMedPubMedCentral
4.
Everhart JE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51(2):585–94.CrossRefPubMed
5.
6.
Seeff LB, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(10):877–83.CrossRefPubMedPubMedCentral
7.
8.
Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Heptology. 2003;38(6):1449–57.CrossRef
9.
10.
Regev A, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–8.CrossRef
11.
Jayakumar, S., S.A. Harrison, and L. R., Noninvasive markers of fibrosis and inflammation in nonalcoholic fatty liver disease. Current Hepatology Reports, 2016. 15(2): p. 86–95.
12.
Lizaola B, et al. Role of noninvasive fibrosis methods in management of chronic hepatitis B virus. Current Hepatology Reports. 2016;15(4):220–9.CrossRef
13.
Weiskirchen R, Tacke F. The role of radiologic modalities in diagnosing nonalcoholic steatohepatitis (NASH) and fibrosis. Current Hepatology Reports. 2018;17(4):324–35.CrossRef
14.
Lejealle C, Castera L. Non-invasive fibrosis testing in patients with chronic hepatitis B. Current Hepatology Reports. 2018;17(4):492–501.CrossRef
15.
A national strategy for the elimination of hepatitis B and C: Phase Two Report, B.L. Strom and G. J. Buckley, Editors. 2017: Washington (DC).
16.
•• AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2018;67:1477–92 Major society guideline from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America governing the evaluation and management of chronic hepatitis C infection.CrossRef
17.
Marrero JA, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.CrossRef
18.
•• European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol, 2018. 69(2): p. 461–511. Major society guideline from the European Association for the study of the liver governing the evaluation and management of chronic hepatitis C infection.
19.
AASLD-IDSA HCV Guidance Panel. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 2015. 62(3): p. 932–954.
20.
Everhart JE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51(2):585–94.CrossRefPubMed
21.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef
22.
Ooka K, Connolly JJ, Lim JK. Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C. Am J Gastroenterol. 2017;112(6):828–32.CrossRefPubMed
23.
Gowda C, et al. Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a National Specialty Pharmacy Cohort Study. Open Forum Infect Dis. 2018;5(6):ofy076.CrossRefPubMedPubMedCentral
24.
Aube C, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 1999;30(3):472–8.CrossRef
25.
Colli A, et al. Severe liver fibrosis or cirrhosis: accuracy of US for detection--analysis of 300 cases. Radiology. 2003;227(1):89–94.CrossRefPubMed
26.
27.
Cohen EI, Wilck EJ, Shapiro RS. Hepatic imaging in the 21st century. Semin Liver Dis. 2006;26(4):363–72.CrossRefPubMed
28.
Talwalkar JA, et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology. 2008;47(1):332–42.CrossRefPubMed
29.
Kanwal F, et al. Hepatitis C virus infection care pathway-a report from the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017;152(6):1588–98.CrossRefPubMed
30.
•• Shiha G, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11(1):1–30 Major society guideline from the Asian Pacific Association for the Study of the liver governing the evaluation and management of chronic hepatitis C infection.CrossRefPubMed
31.
Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection – noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Dig Liver Dis. 2019;51:183–9.CrossRefPubMed
32.
• Chou R, Wasson N. Blood tests to diagnosis fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158:807–20 Comprehensive systematic review summarizing evidence base for noninvasive serum markers for the diagnosis of liver fibrosis or cirrhosis in patients with chronic hepatitis C infection. CrossRef
33.
Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C or B. Aliment Pharmacol Ther. 2016;43:16–29.CrossRefPubMed
34.
Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102:2589–600.CrossRefPubMed
35.
Castera L, et al. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–302.CrossRefPubMed
36.
Fraquelli M, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56(7):968–73.CrossRefPubMedPubMedCentral
37.
Arena U, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58(1):65–72.CrossRefPubMed
38.
Arena U, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut. 2008;57(9):1288–93.CrossRefPubMed
39.
Vispo E, et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther. 2009;14(2):187–93.PubMed
40.
Millonig G, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010;52(2):206–10.CrossRefPubMed
41.
Millonig G, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48(5):1718–23.CrossRefPubMed
42.
Arena U, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47(2):380–4.CrossRefPubMed
43.
Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015;13:27–36.CrossRefPubMed
44.
Degos F, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53(6):1013–21.CrossRefPubMed
45.
Zarski JP, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56(1):55–62.CrossRefPubMed
46.
Castera L, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828–35.PubMed
47.
Sandrin L, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.CrossRef
48.
Castera L, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.CrossRefPubMed
49.
Ziol M, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48–54.CrossRefPubMed
50.
Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102(11):2589–600.CrossRefPubMed
51.
Friedrich-Rust M, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960–74.CrossRef
52.
Afdhal NH, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015;13(4):772–9 e1-3.CrossRefPubMed
53.
Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, et al. Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: a systematic review and meta-analysis. J Viral Hepat. 2018;25:502–13.CrossRefPubMed
54.
Ying HY, Lu LG, Jing DD, Ni XS. Accuracy of trainset elastography in the assessment of chronic hepatitis C-related liver cirrhosis. Clin Invest Med. 2016;39:E150–60.CrossRefPubMed
55.
Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV-HCV coinfection: a systematic review and meta-analysis. J Gastorenterol Hepatol. 2016;31:1684–93.CrossRef
56.
Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573–84.CrossRefPubMedPubMedCentral
57.
Bercoff J, Tanter M, Fink M. Supersonic shear imaging: a new technique for soft tissue elasticity mapping. IEEE Trans Ultrason Ferroelectr Freq Control. 2004;51(4):396–409.CrossRefPubMed
58.
Muller M, et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study. Ultrasound Med Biol. 2009;35(2):219–29.CrossRefPubMed
59.
Abe T, Kuroda H, Fujiwara Y, Yoshida Y, Miyasaka A, Kamiyama N, et al. Accuracy of 2D shear wave elastography in the diagnosis of liver fibrosis in patients with chronic hepatitis C. J Clin Ultrasound. 2018;46:319–27.CrossRefPubMed
60.
Verlinden W, Bourgeois S, Gigase P, Thienpont C, Vonghia L, Vanwolleghem T, et al. Liver fibrosis evaluation using real-time shear wave elastography in hepatitis C-monoinfected and human immunodeficiency virus/hepatitis C-coinfected patients. J Ultrasound Med. 2016;35:1299–308.CrossRefPubMed
61.
Yoneda M, et al. Supersonic shear imaging and transient elastography with the XL probe accurately detect fibrosis in overweight or obese patients with chronic liver disease. Clin Gastroenterol Hepatol. 2015;13(8):1502–9 e5.CrossRefPubMed
62.
Ferraioli G, et al. Reproducibility of real-time shear wave elastography in the evaluation of liver elasticity. Eur J Radiol. 2012;81(11):3102–6.CrossRefPubMed
63.
Gersak MM, et al. Influence of food intake on 2-D shear wave elastography assessment of liver stiffness in healthy subjects. Ultrasound Med Biol. 2016;42(6):1295–302.CrossRefPubMed
64.
Gradinaru-Tascau O, et al. Does experience play a role in the ability to perform liver stiffness measurements by means of supersonic shear imaging (SSI)? Med Ultrason. 2013;15(3):180–3.CrossRefPubMed
65.
Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Miyazaki M, et al. Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients. J Med Virol. 2014;86:241–7.CrossRefPubMed
66.
Frulio N, Trillaud H, Perez P, Asselineau J, Vandenhende M, Hessamfar M, et al. Acoustic radiation force impulse (ARFI) and transient elastography for evaluation of liver fibrosis in HIV-HCV coinfected patients. BMC Infect Dis. 2014;14:405.CrossRefPubMedPubMedCentral
67.
Hu X, Qiu L, Liu D, Qian L. Acoustic radiation force impulse elastography for non-invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason. 2017;19:23–31.CrossRefPubMed
68.
Lopez JJ, Perez-Alvarez N, Rodriguez RV, Jou A, Carbonell P, Jimenez JA, et al. Optimal use of transient elastography and acoustic radiation force impulse to stage liver fibrosis in HIV/HCV-coinfected patients in clinical practice. J Ultrasound Med. 2018;37:113–21.CrossRefPubMed
69.
Popescu A, et al. The influence of food intake on liver stiffness values assessed by acoustic radiation force impulse elastography-preliminary results. Ultrasound Med Biol. 2013;39(4):579–84.CrossRefPubMed
70.
Bota S, et al. The influence of aminotransferase levels on liver stiffness assessed by acoustic radiation force impulse elastography: a retrospective multicentre study. Dig Liver Dis. 2013;45(9):762–8.CrossRefPubMed
71.
Huwart L, et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed. 2006;19(2):173–9.CrossRefPubMed
72.
Huwart L, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40.CrossRefPubMed
73.
Rouviere O, et al. MR elastography of the liver: preliminary results. Radiology. 2006;240(2):440–8.CrossRefPubMed
74.
Rouviere O, et al. MR elastography of the liver: preliminary results. Radiology. 2006;240(2):440–8.CrossRefPubMed
75.
Wang QB, et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology. 2012;56(1):239–47.CrossRefPubMed
76.
Ichikawa S, et al. Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci. 2012;11(4):291–7.CrossRefPubMed
77.
Su LN, et al. Diagnostic value of magnetic resonance elastography for detecting and staging of hepatic fibrosis: a meta-analysis. Clin Radiol. 2014;69(12):e545–52.CrossRefPubMed
78.
Singh S, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13(3):440–451 e6.CrossRefPubMed
79.
• Singh S, et al. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152(6):1544–77 Technical review summarizing available evidence for serum fibrosis markers and liver elastography for assessment of liver cirrhosis in patients with chronic hepatitis C infection.CrossRefPubMed
80.
O'Brien TR, et al. Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology. 2018.
81.
Matsuura K, Tanaka Y. Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatol Res. 2018;48(2):127–33.CrossRefPubMed
82.
Estrabaud E, et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol. 2012;57(5):1110–25.CrossRefPubMed
83.
Romero-Gomez M, et al. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 2011;31(4):443–60.CrossRefPubMed
84.
Noureddin M, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58(5):1548–57.CrossRefPubMedPubMedCentral
85.
Eslam M, et al. FibroGENE: a gene-based model for staging liver fibrosis. J Hepatol. 2016;64(2):390–8.CrossRefPubMed
86.
Huang H, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007;46(2):297–306.CrossRefPubMed
87.
Marcolongo M, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009;50(4):1038–44.CrossRefPubMed
88.
•• European Association for Study of Liver Diseases and H. Asociacion Latinoamericana para el Estudio del, EASL-ALEH Clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015. 63(1): p. 237–64. Major society guideline from EASL and ALEH governing the use of noninvasive tests for assessment of liver fibrosis and cirrhosis.
89.
•• Lim JK, et al. American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of liver fibrosis. Gastroenterology. 2017;152(6):1536–43 Major society guideline from the American Gastroenterological Association governing the role of liver elastography in the evaluation of liver fibrosis and cirrhosis.CrossRefPubMed
90.
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807–20.CrossRef
91.
Castera L, et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52(2):191–8.CrossRefPubMed
92.
Castera L, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.CrossRefPubMed
93.
Sebastiani G, et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther. 2012;35(1):92–104.CrossRefPubMed
94.
Sebastiani G, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49(6):1821–7.CrossRefPubMed
95.
• Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute clinical practice update-expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017;152(6):1578–87 Guidance document from the American Gastroenterological Association with best practice advice on the management of patients with chronic hepatitis C infection who have achieved sustained virologic response (SVR).CrossRefPubMed
Metadata
Title
Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice
Authors
James C. Connolly
Joseph K. Lim
Publication date
01-06-2019
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2019
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-019-00471-3

Other articles of this Issue 2/2019

Current Hepatology Reports 2/2019 Go to the issue

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

The Role of Hepatic and Splanchnic Lymphatic System in Portal Hypertension and Ascites

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring?

Hepatitis C (H Vargas and S Flamm, Section Editors)

HCV Exposure in the Health Care Arena. Is there a Role for Post-exposure Prophylaxis?

Hepatitis C (H Vargas and S Flamm, Section Editors)

Testing for Hepatitis C in Pregnancy: the Time Has Come for Routine Rather than Risk-Based

Hepatitis C (H Vargas and S Flamm, Section Editors)

Hepatitis C-Positive Organs for Liver and Kidney Transplantation—Emerging Data and Current Management Strategies

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Management of Fatigue in Primary Biliary Cholangitis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits